PT  - JOURNAL ARTICLE
AU  - Claudia Marchetti
AU  - Francesca De Felice
AU  - Raffaella Ergasti
AU  - Giovanni Scambia
AU  - Anna Fagotti
TI  - Letrozole in the management of advanced ovarian cancer: an old drug as a new targeted therapy
AID  - 10.1136/ijgc-2019-001128
DP  - 2020 Jul 01
TA  - International Journal of Gynecologic Cancer
PG  - 1058--1064
VI  - 30
IP  - 7
4099  - http://ijgc.bmj.com/content/30/7/1058.short
4100  - http://ijgc.bmj.com/content/30/7/1058.full
SO  - Int J Gynecol Cancer2020 Jul 01; 30
AB  - At present, there is no standard of care on the use of letrozole in ovarian cancer management. We performed a systematic review of the available literature addressing this issue. Data demonstrated a role for letrozole in ovarian cancer, in both the primary and recurrent setting. Letrozole, which has a favorable toxicity profile, seems to assure a prolonged recurrence-free interval, particularly when used as maintenance treatment, in low grade serous ovarian cancer; in recurrent cases it had also led to prolonged disease control. However, the optimal setting and biologically relevant patient population needs to be defined in larger trials.